Article
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Investigational new drugs - 1 Aug 2015
Giri Nagdeep, Masters Joanna C, Plotka Anna, Liang Yali, Boutros Tanya, Pardo Patricia, O'Connell Joseph, Bello Carlo
Abstract excerpt
Dacomitinib (PF-00299804) is a small-molecule inhibitor of the tyrosine kinases human epidermal growth factor receptor-1 (HER1; epidermal growth factor receptor, EGFR), HER2, and HER4 currently being developed for the treatment of lung cancer with sensitizing mutations in EGFR or refractory to EGFR-directed treatment. Dacomitinib is largely metabolized by the liver through oxidative and conjugative metabolism;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.